ProtoKinetix is building value for investors through licensing and joint ventures with business partners, utilizing our internationally patented technology — which is comprised of a family of glycoprotein compounds — targeting biotechnology applications where existing and developing businesses have requirements that AAGPsTM — anti-aging glycopeptides — will dramatically improve.
The biotechnology business is often subject to expensive and time consuming regulatory processes. Our approach is to expedite the development of our technology primarily through business relationships that provide us with leading-edge technical and marketing expertise to expedite the time lines to place products on the shelf.
ProtoKinetix is not about building a business with “bricks and mortar.” We believe there are so many AAGPTM applications that can best be reached through strategic business relationships.
We assess each opportunity with return on investment as the priority. Defining and measuring each agreement based upon corporate investment, time line to market, strength of the organization within a specific market segment and marketing strengths.
As we build the value of AAGPTM we are also taking steps to generate revenue through sales of products in markets that do not require regulatory oversight.
Over the last 5-years, the AAGPTM family of molecules has been examined and explored by numerous scientists, research laboratories, universities and corporations. If there were any flaws in the fundamentals of this science, it would have been exposed long before now. Medicine and research is now accepting the role of peptides in therapeutic medicine and skin care. ProtoKinetix’ glyco peptides are getting more recognition by major biomedical corporations every month and are presently being evaluated as the prime component for therapeutic products in the following areas:
1. Inflammation
2. Allergies
3. Heart attacks
4. Organ transplants
5. Skin care
| 
ProtoKinetix (PKTX)
ProtoKinetix is building value for investors through licensing and joint ventures with business partners, utilizing our internationally patented technology — which is comprised of a family of glycoprotein compounds — targeting biotechnology applications where existing and developing businesses have requirements that AAGPsTM — anti-aging glycopeptides — will dramatically improve.
The biotechnology business is often subject to expensive and time consuming regulatory processes. Our approach is to expedite the development of our technology primarily through business relationships that provide us with leading-edge technical and marketing expertise to expedite the time lines to place products on the shelf.
ProtoKinetix is not about building a business with “bricks and mortar.” We believe there are so many AAGPTM applications that can best be reached through strategic business relationships.
We assess each opportunity with return on investment as the priority. Defining and measuring each agreement based upon corporate investment, time line to market, strength of the organization within a specific market segment and marketing strengths.
As we build the value of AAGPTM we are also taking steps to generate revenue through sales of products in markets that do not require regulatory oversight.
NEWS BRIEFS
Antioxidants to be Showcased at World COnference on Skin Aging.
Over the last 5-years, the AAGPTM family of molecules has been examined and explored by numerous scientists, research laboratories, universities and corporations. If there were any flaws in the fundamentals of this science, it would have been exposed long before now. Medicine and research is now accepting the role of peptides in therapeutic medicine and skin care. ProtoKinetix’ glyco peptides are getting more recognition by major biomedical corporations every month and are presently being evaluated as the prime component for therapeutic products in the following areas:
1. Inflammation
2. Allergies
3. Heart attacks
4. Organ transplants
5. Skin care